Related Experiment Videos
Anticoagulation therapy for radiation-induced myelopathy
C Y Liu1, B T Yim, A J Wozniak
1Department of Pharmacy, Harper Hospital/Karmanos Cancer Institute, Detroit Medical Center, MI 48201-2097, USA. cliu@dmc.org
The Annals of Pharmacotherapy
|February 24, 2001
Summary
This case study explores heparin and enoxaparin as treatments for radiation-induced myelopathy. Anticoagulant therapy showed promise in improving symptoms of spinal cord injury following radiation.
Area of Science:
- Neurology
- Oncology
- Pharmacology
Background:
- Radiation therapy can cause delayed neurologic injury, specifically radiation-induced myelopathy.
- Symptoms include progressive leg numbness and weakness, often linked to vascular compromise in the spinal cord.
Observation:
- A patient with metastatic lung cancer developed radiation-induced myelopathy after treatment.
- Initial steroid treatment provided only brief relief.
Findings:
- Intravenous heparin therapy led to symptom improvement, enabling the patient to walk.
- The patient was subsequently discharged on enoxaparin, indicating potential benefit from anticoagulant therapy.
Implications:
- Heparin and enoxaparin may offer a therapeutic option for radiation-induced myelopathy.
- Anticoagulants might mitigate vascular inflammation and edema contributing to spinal cord injury.